About 95% of all biotech companies probably overpay themselves and closer to 100% give themselves lucrative stock awards year after year. I don't like the sales either but i think you're overstating it a bit.
Are you sure you're not picking on mnta because someone else may not like repros?
The market is pricing mnta like they have about a 10% chance for lovenox approval, which perhaps is the correct way to price the stock since the outcome is impossible for investors to determine. It's not like a normal drug filing where people can pore over data, safety and need and make educated assumptions. This is more like an fda judgement call and an fda that usually errs on the side of caution.
Market Data 
Markets 
AI
